ENvue Medical Secures Three-Year Contract Renewal at 12-Hospital U.S. Health Network as the ENvue™ Navigation Platform Becomes Standard of Care
Rhea-AI Summary
ENvue Medical (NASDAQ: FEED) announced a three-year contract renewal with a leading integrated nonprofit health system operating 12 hospitals in Virginia and North Carolina. The ENvue Navigation Platform has been adopted as the standardized protocol for bedside enteral feeding tube placement across the entire network, embedding the technology into clinical workflow through 2028.
ENvue Medical plans to use this systemwide standardization as a model to pursue similar adoption across additional U.S. health systems.
Positive
- Three-year contract renewal with a 12-hospital integrated nonprofit health system through 2028
- ENvue Navigation Platform adopted as standardized protocol for bedside enteral feeding tube placement across the network
- Standardized protocol embeds ENvue technology into clinical workflow as the method of care, supporting consistent utilization
Negative
- None.
News Market Reaction – FEED
In the May 12 session, FEED gained 1.64%, reflecting a mild positive market reaction. Argus tracked a peak move of +21.3% during that session. Argus tracked a trough of -9.4% from its starting point during tracking. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.5x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 08 | IP allowance | Positive | -9.8% | USPTO Notice of Allowance for ultrasound-enhanced cannabinoid delivery platform. |
| May 07 | GPO renewal | Positive | +5.6% | Three-year GPO purchasing agreement renewal covering 90+ hospitals through 2028. |
| Apr 20 | Hospital milestone | Positive | -4.4% | Announcement of 40th U.S. hospital customer adopting ENvue Navigation Platform. |
| Apr 16 | Corporate update | Positive | -7.5% | Stockholder letter detailing 39 deployed hospitals and 2026 commercial priorities. |
| Mar 24 | Footprint expansion | Positive | +58.0% | Expansion into major Michigan health system, growing footprint to 39 hospitals. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally been positive commercially and strategically, yet price reactions have been mixed, with several selloffs following constructive updates and only two clear positive alignment moves.
Over the past few months, ENvue has reported multiple commercial and strategic milestones. These include expanding its U.S. hospital footprint to 39–40 hospitals, a three-year GPO purchasing renewal through 2028, and new IP such as ultrasound-enhanced cannabinoid delivery. Despite broadly positive headlines, three of the last five news events saw negative next-day reactions, while two, including a major Michigan system expansion, produced sharp gains. Today’s system-level standard-of-care renewal extends this commercialization narrative within U.S. health systems.
Key Terms
enteral feeding tube medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ENvue™ Navigation Platform adopted as the standard of care for bedside feeding tube placement across the integrated health network
TYLER, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced a three-year contract renewal by a leading integrated nonprofit health system operating 12 hospitals across Virginia and North Carolina. The ENvue™ Navigation Platform has been adopted as the standardized protocol for bedside enteral feeding tube placement across all hospitals within the network.
Standardization at the health system level represents significant commercial validation in medical device adoption. Unlike contracted access — which makes a technology available for purchase — a standardized protocol embeds the technology into clinical workflow as the method of care, driving consistent utilization across the network. The Company believes that the three-year renewal confirms that ENvue has achieved and sustained that status within this system and extends the relationship through 2028.
"This renewal is a qualitatively different kind of milestone for ENvue,” said Doron Besser, MD, Chief Executive Officer of ENvue Medical. “Being the standardized protocol across every hospital in a leading integrated health network means our technology is not just available — it is embedded in care. We believe that this validates the clinical performance of our platform in real-world settings and gives us a replicable model we can bring to health systems nationwide."
ENvue Medical remains focused on expanding this standardization model across additional health systems, converting contracted access into active adoption, and building long-term commercial relationships with leading healthcare institutions across the United States.
About ENvue Medical, Inc.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:
- ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
- ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
- Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com
Media Contact:
KCSA Strategic Communications
Michaela Fawcett, Senior Account Director
PH: (978) 995-4683
envue@kcsa.com
